Rhabdomyosarcoma
Conditions
Brief summary
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Interventions
BIOLOGICALmRNA Tumor Vaccine Therapy
personalized mRNA vaccines
Sponsors
Xinxin Zhang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing; 2. Age ≥ 6 years; 3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life; 4. Expected survival time greater than 6 months; 5. ECOG performance status score of 0-1; -
Exclusion criteria
* 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event | From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first. |
Contacts
Primary ContactXinxin Zhang
Outcome results
None listed